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of the Journal was undertaken to describe contemporary
practice patterns and outcomes of lung volume reduction
surgery (LVRS) on a national level, using data obtained
from the Society of Thoracic Surgeons (STS) database.
The resulting analysis is compared with published results
of the National Emphysema Treatment Trial (NETT).
The authors, as have many others, question why
application of a procedure demonstrated by the NETT to
be so effective for selected patients with emphysema has
languished, despite the prevalence of chronic obstructive
pulmonary disease.
The STS database was found to contain 538 patients who
underwent LVRS over the 8.5-year span covered by the
study. However this database is voluntary, so it may or
may not be representative of the majority of cases
performed in the United States. It contains aggregate de-
identified data that does not permit retrospective data
mining or subgroup analysis to be conducted. Postoperative
data, including morbidity and mortality, is limited to 30
days and does not include either subjective or objective
measures of improvement. In comparison with the NETT
trial, which included only patients undergoing bilateral
LVRS, the STS database cannot distinguish between
unilateral and bilateral procedures that have previously
been documented to result in differing postoperative
mortality and functional outcome. In addition, the limited
data designed to be captured by the STS database are often
incomplete. For example, 30-day mortality was missing for
14% of patients so, as the authors indicate, the post-LVRS
30-day mortality of 5.6% might actually range from 4.8%
up to 19.6% depending on how many of the patients with
unknown status were actually alive at 30 days. Furthermore
the NETT trial demonstrated that postoperative mortalityFrom the University of Pennsylvania Health System, Philadelphia, Pa.
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2470 The Journal of Thoracic and Cardiovascular Surfollowing LVRS continues to rise significantly between
30 and 90 days (2.2% and 5.2%, respectively) preventing
accurate comparison between the study by Decker and col-
leagues1 and the NETT data. The authors cite a 36% rate of
missing STS data for each of the other outcome variables,
and highlight the significant differences in preoperative
characteristics between STS database patients and NETT
patients. The fact that 34.5% of patients in the STS database
who underwent LVRS are reported as ‘‘never smoked’’
strains credibility. These factors, together with the absence
of any postoperative functional data in the STS group
emphasize the limitations of this study, all of which are
duly noted by the authors.
By attempting to compare STS data with data from the
NETT trial, Decker and colleagues1 also highlight impor-
tant limitations and deficiencies of the NETT trial. The
NETT trial, a randomized comparison between best medi-
cal practice and LVRS, compared outcomes in terms of
mortality, exercise capacity, quality of life, pulmonary
function studies, and other factors.2 Based on information
available from prior LVRS reports, the NETT trial had a
hypothesis that stated that patients with emphysema
who improve following LVRS will preoperatively have
‘‘heterogeneously distributed emphysema involving the
upper lung zones predominately’’ (Minutes of NETT Steer-
ing Committee, March 24-25 1997). However the actual
NETT trial inclusion criteria included many patients who
did not meet this hypothesis so as ‘‘to include all patients
who might benefit.’’ Thus more than 50% of patients under-
going LVRS in the NETT did not meet the hypothesis
criteria.3 Furthermore 2 years into the study, disappointing
enrollment prompted a change in inclusion criteria,
allowing a group of high-risk patients, initially excluded,
to be enrolled. A subsequent interim NETT publication re-
ported that LVRS in these patients was associated with a 90-
day postoperative mortality rate of 30% and insignificant
benefit for those who survived. This group, subsequently
referred to as the ‘‘high-risk group,’’ was once again re-
excluded from the trial.
The definitive NETT report based upon 2-year follow-up
data, was published in 2003. This report soon became as
controversial as the procedure it was intended to evaluate.
Although demonstrating marked improvement in exercise
capacity, health-related quality of life, pulmonary function
studies, and others outcome measurements for patients un-
dergoing LVRS, these were considered secondary outcomes
and final recommendations weremade primarily on the basis
of mortality advantage, which was the preselected primarygery c December 2014
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demonstrated survival benefit at 2 years for a limited number
of NETT patients described as having an upper lobe predom-
inant pattern of emphysema and retrospectively classified as
having ‘‘low baseline exercise capacity.’’ The survival
advantage for LVRS in this group was based solely on the
early high mortality rate of the corresponding patients ran-
domized to medical therapy.
A later publication by the NETT group4 3 years later
included 40%more patients with available 2-year outcome
data and confirmed the 5-year survival advantage of LVRS
for the overall group of nonhigh-risk NETT LVRS patients
when compared with medical therapy.
A major limitation of the NETT report is the data presen-
tation, which is confusing, highly statistically complicated,
and difficult to understand, thus defying the ability to
compare itwith any other published report onLVRS. The his-
tograms used to compare outcomes betweenmedical and sur-
gical groups do confirm statistical superiority of LVRS over
corresponding medical groups, but do not quantify the
magnitude of improvement nor allow easy determination of
the percent of surviving patients showing improvement at
each time point. Furthermore no analysis was presented for
the overall subgroup of patients meeting the original NETT
hypothesis. It has been noted by others that judging the suc-
cess or failure only on survival is inadequate and that ‘‘every
published randomized-controlled trial has shown that LVRS
improves symptoms and functioning in survivors.’’5
Despite all the misunderstanding and controversy gener-
ated by the NETT trial, it was a very comprehensive, well-
organized, and meticulously constructed and conducted
trial with strict, well-defined prospectively acquired pre-
and postoperative data. It is a vast database, now available
under the Freedom of Information Act, that has been used
as a source for many subsequent publications. On the basis
of the NETT results, Medicare resumed funding for LVRS.
The scientific conclusions that can be derived from
Decker and colleagues’ current publication1 are quite
limited. However the authors are to be congratulated for
their overall observations and the recommendations madeThe Journal of Thoracic and Carin their final comments. Underuse of LVRS highlights the
paradox that the NETT trial, which has established the
benefit achieved by LVRS for appropriate patients, may
have significantly limited the very procedure whose value
it has confirmed. The pulmonary medicine community
has accepted the principle that reduction of hyperinflation
in selected patients with chronic obstructive pulmonary dis-
ease can produce significant functional, quality of life, and
survival benefit as judged by the multiple attempts to
achieve similar benefit by a variety of endoscopic proce-
dures. Yet none of these has demonstrated sufficient effec-
tiveness to warrant approval in the United States while
referrals for LVRS are few and far between.
There have been more than enough experience, publica-
tions, and clinical trials of LVRS to analyze, clarify, and
define its appropriate role, risks, and benefits. Decker and
colleagues1 suggest what is now needed is consensus on
how to ensure that LVRS is appropriately used and the
importance of developing multidisciplinary centers for
the treatment of advanced respiratory disease for both sur-
gical and medical management of emphysema. This publi-
cation, although confirming the difficulty in comparing
apples and oranges, may by its recommendations produce
an improved product, confirming yet again the adage that
when confronted with lemons, the best thing to do is
make lemonade.
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